Three major health information companies (IMS Health, Versipan and Wolters Kluwer Health) have issued a joint statement concerning the preliminary injunction hearing on a state law (Maine LD-4) that would prevent the gathering of prescribing information from health care professionals for "drug marketing purposes" (Marketletter December 3). The court case in the northeastern state of Maine follows a recent victory by the firms against a similar law in neighboring New Hampshire (Marketletters passim).
The joint statement declares: "we simply believe that the Maine statute is not good health care policy. The key to improving health care quality, and reducing costs and variability in treatment is access to more information - not less. Provider-level prescription data is a critical resource in this information flow for all stakeholders."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze